Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tafamidis 61mg, Outcomes in ATTR Amyloidosis With Neurologic and Multisystemic Involvement - TRAMA

NCT05560555 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05560555
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05560555 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tafamidis 61mg, Outcomes in ATTR Amyloidosis With Neurologic and Multisystemic Involvement - TRAMA
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
October 24, 2022
Completion date
November 15, 2022
Enrollment
5 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary transthyretin amyloidosis (attrv), polyneuropathy